ALZAI Health Corp. Lists on OTCQB Venture Market
News related to:ALZAI Health Corp · 2 min read
ALZAI Health Corp., a healthcare technology company based in Ontario, has announced that its common shares are now listed for trading on the OTCQB Venture Market in the United States under the symbol ALZIF. This development marks a significant expansion of the company's market presence, allowing for greater accessibility to U.S. investors. The OTCQB Venture Market, operated by OTC Markets Group Inc., is a platform designed to provide improved market visibility and access to early-stage and developing companies. By listing on the OTCQB, ALZAI Health Corp. aims to broaden its U.S. capital markets presence, increase its visibility and awareness among U.S. investors, and provide greater accessibility to its common shares.
ALZAI Health Corp. was founded to develop non-invasive, artificial intelligence-driven disease risk identification solutions using routine healthcare data. The company's proprietary platform is designed to identify individuals at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. The technology has been validated on large-scale healthcare datasets and is designed for integration into existing healthcare infrastructure, including electronic medical record systems, cloud-based environments, and enterprise healthcare platforms.
The company's common shares continue to trade on the TSX Venture Exchange under the symbol ALZI and on the Frankfurt Stock Exchange under the symbol H2F. The new listing on the OTCQB is expected to enhance the liquidity and trading activity of the shares, providing ALZAI Health Corp. with a broader platform to engage with U.S. investors. The OTCQB Venture Market is specifically designed to support early-stage and developing companies, offering them a pathway to increased visibility and market access.
ALZAI Health Corp. is led by Hayim Raclaw, the Chairman and Chief Executive Officer.
The company's technology has been validated on large-scale healthcare datasets, demonstrating its potential to revolutionize disease risk identification. By integrating AI-driven solutions into existing healthcare infrastructure, ALZAI Health Corp. aims to support earlier intervention and improved patient outcomes. The company's platform is designed to be flexible and scalable, allowing for seamless integration into various healthcare systems.
The TSX Venture Exchange listing under the symbol ALZI and the Frankfurt Stock Exchange listing under the symbol H2F will continue alongside the new OTCQB listing. This multi-market strategy is expected to provide ALZAI Health Corp. with a more comprehensive reach and increased exposure to a wider range of investors.
ALZAI Health Corp. remains committed to developing innovative solutions that can improve patient outcomes and support the healthcare industry. The company's listing on the OTCQB is seen as a step towards achieving these goals and enhancing its position in the healthcare technology sector. The company's technology has the potential to significantly impact the early detection and management of diseases, ultimately contributing to better health outcomes for individuals and communities.
The new listing on the OTCQB Venture Market is effective as of October 20, 2026, marking a pivotal moment for ALZAI Health Corp. as it continues to advance its mission of improving patient care through cutting-edge technology.